CEL-SCI CORPORATION Increase (Decrease) in Accounts Receivable
CEL-SCI CORPORATION (CVM) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2018-09-30, per its 10-K filed 2018-12-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2018-12-19
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for the quarter ending 2018-09-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for the quarter ending 2018-06-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for the quarter ending 2018-03-31 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for fiscal 2018 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for fiscal 2017 was -$305.34K, a 200.00% decline from fiscal 2016.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for fiscal 2016 was $305.34K.
- CEL-SCI CORPORATION increase (decrease) in accounts receivable for fiscal 2015 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-19 | $0.00 derived: sum of 2 quarters · filed 2018-12-19 | $0.00 derived: sum of 3 quarters · filed 2018-12-19 | $0.00 10-K · filed 2018-12-19 |
| 2018-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | $0.00 derived: sum of 2 quarters · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | -$610.68K derived: sum of 4 quarters · filed 2018-12-19 |
| 2018-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | $0.00 10-Q · filed 2018-05-15 | -$610.68K derived: sum of 3 quarters · filed 2018-12-19 | -$610.68K derived: sum of 4 quarters · filed 2018-12-19 |
| 2017-12-31 | $0.00 10-Q · filed 2018-02-12 | -$610.68K derived: sum of 2 quarters · filed 2018-12-19 | -$610.68K derived: sum of 3 quarters · filed 2018-12-19 | -$610.68K derived: sum of 4 quarters · filed 2018-12-19 |
| 2017-09-30 | -$610.68K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-19 | -$610.68K derived: sum of 2 quarters · filed 2018-12-19 | -$610.68K derived: sum of 3 quarters · filed 2018-12-19 | -$305.34K 10-K · filed 2018-12-19 |
| 2017-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | $0.00 derived: sum of 2 quarters · filed 2018-08-14 | $305.34K 10-Q · filed 2018-08-14 | $247.38K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | $305.34K 10-Q · filed 2018-05-15 | $247.38K derived: sum of 3 quarters · filed 2018-05-15 | $311.99K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $305.34K 10-Q · filed 2018-02-12 | $247.38K derived: sum of 2 quarters · filed 2018-02-12 | $311.99K derived: sum of 3 quarters · filed 2018-02-12 | $244.41K derived: sum of 4 quarters · filed 2018-02-12 |
| 2016-09-30 | -$57.96K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-12-29 | $6.65K derived: sum of 2 quarters · filed 2017-12-29 | -$60.93K derived: sum of 3 quarters · filed 2017-12-29 | $305.34K 10-K · filed 2017-12-29 |
| 2016-06-30 | $64.61K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-12-11 | -$2.97K derived: sum of 2 quarters · filed 2017-12-11 | $363.30K 10-Q/A · filed 2017-12-11 | |
| 2016-03-31 | -$67.57K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-12-11 | $298.69K 10-Q/A · filed 2017-12-11 | ||
| 2015-12-31 | $366.27K 10-Q/A · filed 2017-12-11 | |||
| 2015-09-30 | $0.00 10-K/A · filed 2017-12-11 | |||
| 2014-09-30 | $0.00 10-K/A · filed 2017-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |